| Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm. | |
| | |
MedLine Citation:
|
PMID: 18313448 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The normal pituitary production of human chorionic gonadotropin alongside luteinizing hormone, measurable in menopausal serum and urine was initially reported over 3 decades ago and has been described in numerous subsequent publications. Unfortunately, delays or cancellations of important medical procedures and use of needless chemotherapy still occurs because of the finding of human chorionic gonadotropin in perimenopausal and postmenopausal woman. We describe the problem and a concise approach to this management dilemma in menopausal women. STUDY DESIGN: This is an outcomes study of 36 cases of perimenopausal and postmenopausal human chorionic gonadotropin evaluated in cases referred to the USA hCG Reference Service. RESULTS: By report of the provided records, in 6 of 36 cases, unneeded chemotherapy was given for assumed recurrent gestational trophoblastic disease. In 9 cases, surgery was cancelled or postponed and in 3 cases renal transplantation was cancelled at the time of locating a matched donor kidney. In all cases the measured human chorionic gonadotropin was due to menopausal production of pituitary human chorionic gonadotropin. The average human chorionic gonadotropin detected in perimenopausal cases was 6.4 +/- 3.2 IU/L, and in postmenopausal cases was 11.6 +/- 7.0 IU/L or significantly higher. In 24 cases, therapeutic doses of high-estrogen birth control pill were used to confirm pituitary origin with 23 cases demonstrating successful human chorionic gonadotropin suppression. CONCLUSION: Low levels of human chorionic gonadotropin production in the perimenopausal and postmenopausal state is a normal physiologic phenomenon. Provider education is warranted and management protocols are suggested in all health-related fields to clarify the normality of low level pituitary human chorionic gonadotropin production. Understanding this physiology will avoid delays in necessary therapies such as organ transplants, and will limit the misadventure of prescribing unnecessary treatments for presumed gestational malignancy. |
| | |
Authors:
|
Laurence A Cole; Sarah A Khanlian; Carolyn Y Muller |
Related Documents
:
|
16515638 - Primary "breast-like" cancer of the vulva: a case report and critical review of the lit... 2172688 - Parvovirus and epidemic arthritis. 10299248 - Medicare program; administrator's review of provider reimbursement review board decisio... 19450078 - A critical review of the full economic evaluations of pharmacological treatments for gl... 8723558 - Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell c... 9306668 - Bevelling in exit gunshot wounds in bones. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of obstetrics and gynecology Volume: 198 ISSN: 1097-6868 ISO Abbreviation: Am. J. Obstet. Gynecol. Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-03-03 Completed Date: 2008-04-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370476 Medline TA: Am J Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 275.e1-7 Citation Subset: AIM; IM |
Affiliation:
|
USA hCG Reference Service, Department of Obstetrics and Gynecology, University of New Mexico Albuquerque, NM, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Chorionic Gonadotropin / blood* Female Genital Diseases, Female / blood Humans Middle Aged Perimenopause / blood* Postmenopause / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Chorionic Gonadotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physical therapy evaluation of patients with chronic pelvic pain: a controlled study.
Next Document: Maternal C-reactive protein and developmental programming of atherosclerosis.